CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Avant Genomics Secures $3M+ in Funding to Accelerate First-in-kind Automated Platform for Liquid Biopsy Sample Preparation

From BioSpace

May 12, 2026

Avant Genomics Secures $3M+ in Funding to Accelerate First-in-kind Automated Platform for Liquid Biopsy Sample Preparation

Avant Genomics Secures $3M+ in Funding to Accelerate First-in-kind Automated Platform for Liquid Biopsy Sample Preparation
Avant Genomics, a pioneer in fully-automated liquid biopsy sample preparation for precision cancer detection, today announced the successful raise of more than $3 million to advance development of its automated platform for liquid biopsy sample preparation. TitletownTech, Halyard Ventures, Virginia Venture Partners, CAV Angels, Global Impact Fund, and additional angel investors and family offices participated in the round. The new capital will support continued R&D, accelerate manufacturing, and expand the team expertise with additional hires. The Avant Source platform is designed to standardize and automate liquid biopsy sample preparation, reducing manual handling from more than 50 steps to two, while improving DNA yield by as much as 70% compared to semi-automated tools and cutting processing time in half.

View original article on biospace.com

Most Recent

Global Smartphone Shipments Drop Record High of 22% in Q3 2026 as the Memory Crisis Hits Hard, According to IDC

Global smartphone shipments fell 22% to 255.3M units in 3Q26, a record drop driven by memory costs. IDC expects no recovery before 2028.

Oct 14, 2026

Travel + Leisure Co. Completes $300 Million Term Securitization

ORLANDO, Fla.--(BUSINESS WIRE)-- Travel + Leisure Co. (NYSE:TNL) announced today it completed a term securitization transaction involving the…...

Oct 14, 2026

PC Market Woes Continue: Shipments Fall 20.1% in Q3 2026 as Pull-In Hangover and Supply Constraints Bite

Seasonal third quarter lift fails to materialize after vendors and channels front-loaded inventory ahead of price hikes

Oct 9, 2026

Rebel Audio Raises Series A at $50 Million Valuation Post-Money, Backed by Creator Media Company HardScope

Newly Established Board Of Directors includes DraftKings Founder & HardScope CEO Matt Kalish, Ben Lurie, Jacob Dezarn, and Jonathan Schulman alongside Advisory Board Members Mark Burnett and Chief Creator in Residence Mike Majlak

Oct 9, 2026

Similar Posts

Molecular Stethoscope Completes $8.2M Seed Financing to Advance Circulating Cell-Free RNA Liquid Biopsy Platform; Announces Research Collaboration with Pfizer

Molecular Stethoscope closed an $8.2 million seed round backed by DCVC (Data Collective), Pfizer, Index Ventures and a leading U.S. research university, and signed a two-year research collaboration with Pfizer to build a blood-based assay for cardiometabolic disease progression. The company said the proceeds would fund development of its first-in-class liquid biopsy tests built on circulating cell-free RNA.

Jan 5, 2017

Support automation firm Capacity grows with new cash and acquisitions

David Karandish has been busy. Capacity, his support automation company, was planning a $5 million “bridge round” to help the company reach the break-even point. But TVC Capital, Toloka.vc, and the venture’s other backers had something grander in mind. So they threw in an additional $21 million for what became Capacity’s $26 million Series D. While all this was happening, Capacity acquired three companies: enterprise search firm Lucy (which had raised $5.6 million) and two startups focused on c

Oct 16, 2024

Volta Labs Launches Callisto to Revolutionize Genomics and Sample Prep

Volta Labs announced the commercial launch of Callisto, its automated sample-preparation platform for genomic sequencing.

Jan 31, 2024

Startup Evvy raises $40M to accelerate precision diagnostics and medicine for women’s health

Evvy, an artificial intelligence startup that’s looking to enhance women’s healthcare, said today it has closed on $40 million in Series B funding to scale its precision diagnostics and care platform. The round was led by Catalio Capital Management, with new investors including the U.S. Fertility In

Sep 15, 2026